INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 459m ago
HOUSE PTR58m ago
SEC 13F58m ago
ROBINHOOD CHAIN58m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Lyssikatos Joseph P sold ELVN

CHIEF SCIENTIFIC OFFICER · Enliven Therapeutics, Inc. · Common Stock

Side
SELL
Value
$145K
Shares
5,491
Price
$26.37
Executed
Jan 20, 2026
Disclosed
Jan 22, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 20 executedJan 22, 2026 disclosed

ELVN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
6/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+4 / 25

    $145K reported value · 0.7% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 7 prior trades recorded in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ELVN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    CL
    Collins Helen LouiseCHIEF MEDICAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    5,000 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    0
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$89K
    6,018 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CL
    Collins Helen LouiseCHIEF MEDICAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$12K
    5,000 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    0
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    6,018 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    10
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$232K
    6,018 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    10
    CL
    Collins Helen LouiseCHIEF MEDICAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$192K
    5,000 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    0
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    3,982 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    6
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$15K
    289 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    13
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$111K
    2,194 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    2
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$59K
    3,982 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    13
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$177K
    3,535 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    0
    CL
    Collins Helen LouiseCHIEF MEDICAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    5,000 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    6
    CL
    Collins Helen LouiseCHIEF MEDICAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$12K
    240 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    13
    CL
    Collins Helen LouiseCHIEF MEDICAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$94K
    1,844 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    13
    CL
    Collins Helen LouiseCHIEF MEDICAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$146K
    2,916 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    3
    CL
    Collins Helen LouiseCHIEF MEDICAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$12K
    5,000 sh
    		Sep 17, 2026Sep 21, 2026
    traded Sep 17, 2026
    		+4dSEC FORM 4

    Evidence

    11
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$270K
    4,630 sh
    		Aug 17, 2026Aug 19, 2026
    traded Aug 17, 2026
    		+2dSEC FORM 4

    Evidence

    4
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$82K
    1,388 sh
    		Aug 17, 2026Aug 19, 2026
    traded Aug 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    6,018 sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    18
    HB
    Hohl BenjaminCHIEF FINANCIAL OFFICER
    ELVNEnliven Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$149K
    3,401 sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001967150-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 20, 2026
    Published
    Jan 22, 2026
    Ingested by INSIDER
    Nov 5, 04:21 UTC
    Last re-read
    Nov 5, 04:21 UTC

    Extracted facts

    Filer
    Lyssikatos Joseph P
    Role
    CHIEF SCIENTIFIC OFFICER
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Enliven Therapeutics, Inc.
    Ticker
    ELVN
    Shares
    5,491
    Price per share
    $26.37
    Value
    $144,814
    Execution date (reported)
    Jan 20, 2026
    Owned after transaction
    759.7K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 5,491
    • Price: $26.373

    = $144,814

    What this establishes

    Lyssikatos Joseph P filed this Form 4 reporting a open-market sale of ELVN on Jan 20, 2026. It became public on Jan 22, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    CHIEF SCIENTIFIC OFFICER
    Lyssikatos Joseph Pcik:0001967150
    Issuer
    Enliven Therapeutics, Inc.cik:0001672619

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.